Skip to main content

Glucagon-like peptide-1 agonists

07-20-2023 | Type 2 diabetes | News

Triple agonist shows promise for both glycemic and weight control

Treating people with type 2 diabetes with the triple agonist retatrutide shows promising improvements in both glycemic control and reduction in obesity.

03-17-2022 | Glucagon | News

Mini-dose glucagon better than glucose tablets for Ramadan hypoglycemia

Subcutaneous mini-dose glucagon reverses hypoglycemia more effectively than oral glucose tablets and helps adults with type 1 diabetes complete Ramadan fasts, shows a randomized crossover trial.

05-07-2021 | Glucagon | News

Dasiglucagon promising for severe hypoglycemia in children with type 1 diabetes

Dasiglucagon, a next-generation glucagon analog in a ready-to-use formulation, rapidly restores plasma glucose levels following severe hypoglycemia in children and adolescents with type 1 diabetes, show findings from a phase 3 trial.

06-11-2019 | Glucagon | ADA 2019 | News

Phase III data support dasiglucagon use for severe hypoglycemia

Dasiglucagon has potential as a fast, effective treatment for severe hypoglycemia in patients with type 1 diabetes, show phase III study data presented at the 79th ADA Scientific Sessions in San Francisco, California, USA.

Treadmill

05-25-2018 | Hypoglycemia | Highlight | News

Mini-dose glucagon could help protect against exercise-induced hypoglycemia

Modestly increasing glucagon levels when commencing physical activity could be an effective strategy for preventing exercise-induced hypoglycemia among patients with type 1 diabetes, results of a randomized crossover trial suggest.

01-03-2018 | Glucagon | News

Glucagon use restrictions compromising prehospital hypoglycemia treatment in USA

The widespread bar on glucagon administration by basic providers of emergency medicine in the USA may prevent its use in three-quarters of cases in which it is needed, say researchers.